As mentioned earlier, RUNX1 and NRAS mutations were driving factors of leukemic transformation, while SRSF2 was identified as a hazard for increased mortality in patients with AML harboring ASXL1mt.34 This evidence concerns the gene SRSF2 and acute myeloid leukemia.